Atezolizumab Helps Prolong Overall Survival in Patients with Bladder Cancer

A study from the phase III IMvigor211 trial, has revealed that the anti-PD-L1 immune checkpoint inhibitor atezolizumab discusses survival gain in patients with locally advanced or metastatic urothelial carcinoma or mUC treated with platinum-containing chemotherapy.

Photo: Bladder Cancer | InStyleHealth


Current analysis covered the IMvigor211 intent-to-treat or ITT population. The study comprised of mUC patients who progressed during or following platinum-based chemotherapy and were randomly assigned to receive either atezolizumab 1,200 mg or chemotherapy (vinflunine 320 mg/m2, paclitaxel 175mg/m2, or docetaxel 75mg/m2; choice of regimen at researcher’s discretion) intravenously every 3 weeks.

Atezolizumab generated long-term durable remission over a median follow-up of 33 months as compared with chemotherapy. Despite the primary analysis showcasing no statistically significant effect on overall survival.

The overall survival or OS rates at 24 months were more favorable with atezolizumab than with chemotherapy which only has 13% OS vs 23% OS for atezolizumab.

Outcomes for safety were in line with the primary analysis, and no new signals emerged. Higher grade treatment-related adverse events or AEs occurred more frequently among chemotherapy-treated patients, as were AEs that led to treatment discontinuation.

Meanwhile, AEs of special interest, which tended to be grade 1-2, were more prevalent among patients who received atezolizumab, 35% vs 20%.

Regardless of PD-L1 status, the results support the use of atezolizumab in mUC patients treated with platinum-based chemotherapy.

 

Source: Eur Urol 2021;doi:10.1016/j.eururo.2021.03.024

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post